# Safety and Efficacy of TollB-001 Tablets in Moderate to Severe Rheumatoid Arthritis

> **NCT07408024** · PHASE2 · RECRUITING · sponsor: **Toll Biotech Co. Ltd. (Beijing)** · enrollment: 24 (estimated)

## Conditions studied

- Rheumatoid Arthritis (RA)

## Interventions

- **DRUG:** Group 1: TollB-001 100mg qd po; Group 2: TollB-001 200mg qd po; Group 3: TollB-001400mg qd po
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07408024
- **Lead sponsor:** Toll Biotech Co. Ltd. (Beijing)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-10
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07408024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07408024, "Safety and Efficacy of TollB-001 Tablets in Moderate to Severe Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07408024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*